Search results for "anticonvulsant"

showing 10 items of 141 documents

Natural Course, Clinical Profile, and Treatment Strategies for Cerebral Cavernous Malformations

2022

A large body of evidence has suggested that the natural biology for symptomatic cerebral cavernous malformations (CCMs) is dynamic. These lesions exhibit a temporal clustering epiphenomenon and usually manifest with multispectral clinical patterns, the most relevant being hemorrhagic and seizurogenic events. Most patients with cerebral cavernous malformations are asymptomatic, and the lesions are detected as incidentalomas. However, association with the CCM3 gene, Zabramski type I and II lesions, and brainstem location have the propensity to increase the bleeding events. The rebleeding risk is 20%/year per lesion, which supports the need for surgical strategies for brainstem cavernous malfo…

CavernomaHemangioma Cavernous Central Nervous SystemSeizuresHumansAnticonvulsantsSurgeryNeurology (clinical)PresentationCourseRadiosurgeryBrain StemManagementWorld Neurosurgery
researchProduct

Loss of input from the mossy cells blocks maturation of newly generated granule cells.

2007

The objective of this work is to check whether the input from the mossy cells to the inner molecular layer is necessary for the integration and maturation of the newly generated granule cells of the dentate gyrus (DG) in mice, and if after status epilepticus the sprouting of the mossy fibers can substitute for this projection. Newly generated cells were labeled by administration of 5-bromo-deoxyuridine either before or after pilocarpine administration. The neuronal loss in the hippocampus after administration of pilocarpine combined with scopolamine and diazepam seemed restricted to the hilar mossy cells. The maturation of the granule cells was studied using immunohistochemistry for calreti…

Cell typeCell SurvivalCognitive NeuroscienceScopolamineConvulsantsNerve Tissue ProteinsMuscarinic Antagonistschemistry.chemical_compoundMiceS100 Calcium Binding Protein GStatus EpilepticusmedicineAnimalsCell ProliferationDiazepamEpilepsyNeuronal PlasticitybiologyChemistryDentate gyrusStem CellsGranule (cell biology)PilocarpineNuclear ProteinsCell DifferentiationImmunohistochemistryDNA-Binding Proteinsnervous systemBromodeoxyuridinePilocarpineCalbindin 2Dentate GyrusMossy Fibers HippocampalNerve Degenerationbiology.proteinAnticonvulsantsFemaleNeuNCalretininNeuroscienceBromodeoxyuridineBiomarkersSproutingmedicine.drugHippocampus
researchProduct

Determination of Anticonvulsant Drugs in Pharmaceutical Preparations by Micellar Liquid Chromatography

2004

A micellar liquid chromatographic method for quality control of pharmaceutical preparations (capsules, pills, tablets, injections, drops, and suppositories) containing the anticonvulsant drugs acetazolamide, carbamacepine, chlordiazepoxide, diazepam, ethosuximide, phenytoin, phenobarbital, and zopiclone has been developed. This methodology involves the use of micellar solutions of cetyltrimethylammonium bromide (CTAB) as mobile phases and UV detection. The proposed approach is rapid and reproducible. Sample preparation only requires dissolution with micellar solvent and adequate dilution with the mobile phase before injection into the chromatographic system.

ChromatographyChemistrymedicine.medical_treatmentClinical Biochemistrytechnology industry and agriculturePharmaceutical ScienceBiochemistryDosage formAnalytical ChemistryChlordiazepoxideSolventEthosuximideAnticonvulsantMicellar liquid chromatographyMicellar solutionsmedicinelipids (amino acids peptides and proteins)Sample preparationmedicine.drugJournal of Liquid Chromatography & Related Technologies
researchProduct

Quantitative analysis of mixtures of metal-carbonyl complexes by Fourier-transform infrared spectroscopy: application to the simultaneous double immu…

1996

Abstract The feasibility of a double immunoassay of haptens by the nonisotopic carbonyl metalloimmunoassay (CMIA) method is demonstrated. Three different pairings of antiepileptic medications from the groups carbamazepine, diphenylhydantoin, and phenobarbital (for each of which a mono-CMIA is already available) were assayed by double CMIA. The assay method employs as tracers metal–carbonyl complexes that give very strong signals in the range of 1850–2200 cm −1 in the infrared spectrum, permitting quantitative analysis by Fourier-transform infrared spectroscopy. The fact that the signals are individually assignable and of comparable intensity permits quantitative analysis of mixtures of two …

Correlation coefficientInfraredBiophysicsAnalytical chemistryInfrared spectroscopyMetal carbonylBiochemistryAbsorbanceSpectroscopy Fourier Transform InfraredmedicineOrganometallic CompoundsAnimalsHumansFourier transform infrared spectroscopyMolecular BiologyImmunoassayChromatographymedicine.diagnostic_testMolecular StructureChemistryCell BiologyCarbamazepineEvaluation Studies as TopicImmunoassayPhenobarbitalPhenytoinAnticonvulsantsQuantitative analysis (chemistry)HaptensAnalytical biochemistry
researchProduct

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Levetiracetam.

2015

Literature and experimental data relevant for the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing levetiracetam are reviewed. Data on solubility and permeability suggest that levetiracetam belongs to class I of the biopharmaceutical classification system (BCS). Levetiracetam's therapeutic use, its wide therapeutic index, and its favorable pharmacokinetic properties make levetiracetam a valid candidate for the BCS-based biowaiver approach. Further, no BE studies with levetiracetam IR formulations in which the test formulation failed to show BE with the comparator have been reported in the open lit…

Dosage FormsSolid oral dosage formLevetiracetamChemistryChemistry PharmaceuticalPharmaceutical ScienceBiological AvailabilityPharmacologyBioequivalencePiracetamDosage formPermeabilityBiopharmaceuticsReference productBiopharmaceuticalTherapeutic EquivalencymedicineAnimalsHumansAnticonvulsantsLevetiracetamImmediate releasemedicine.drugJournal of pharmaceutical sciences
researchProduct

Oxcarbazepine does not affect the anticoagulant activity of warfarin.

1992

The possible interaction of the antiepileptic drug oxcarbazepine (OCBZ) on the anticoagulant effect of warfarin was investigated in 10 healthy male volunteers. After reaching steady-state conditions by repeated administration of warfarin, the prothrombin time (Quick value) was assessed before and after single (600 mg) and multiple dosing (450 mg twice daily in 1 week) of OCBZ. In 7 of the 10 volunteers with evaluable data, the prothrombin time was not significantly different (paired t test) from baseline either after single (p = 0.299) or repeated dosing (p = 0.333), indicating that OCBZ does not interact to any relevant extent with the hypothrombinemic effect of warfarin.

DrugAdultMalemedicine.drug_classmedia_common.quotation_subjectmedicine.medical_treatmentOxcarbazepinePharmacologymedicineHumansDrug InteractionsOxcarbazepineBlood Coagulationmedia_commonProthrombin timeChemotherapymedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryAnticoagulantWarfarinDose–response relationshipAnticonvulsantCarbamazepineNeurologyAnesthesiaProthrombin TimeAnticonvulsantsNeurology (clinical)Warfarinbusinessmedicine.drugEpilepsia
researchProduct

Micellar electrokinetic capillary chromatography for therapeutic drug monitoring of carbamazepine and its main metabolites.

1998

In carbamazepine (CBZ) therapy the concomitant monitoring of concentrations of CBZ and its metabolites is strictly recommended, primarily to avoid toxic side effects. Currently, clinical routine monitoring of CBZ is accomplished by high-performance liquid chromatography or immunological methods. In this study a micellar electrokinetic capillary chromatographic (MECC) method was developed for routine drug monitoring of CBZ and its main metabolites, carbamazepine 10,11-diol and carbamazepine 10,11-epoxide, in human serum or plasma samples. The MECC method enabled baseline separation of all analytes within 2.5 min. The assay revealed sufficient precision and sensitivity and the results of eith…

DrugAnalyteChromatographymedicine.diagnostic_testChemistrymedia_common.quotation_subjectMetabolitemedicine.medical_treatmentElectrophoresis CapillaryGeneral ChemistryCarbamazepineHigh-performance liquid chromatographyMicellar electrokinetic chromatographychemistry.chemical_compoundAnticonvulsantCarbamazepineTherapeutic drug monitoringmedicineHumansAnticonvulsantsDrug MonitoringChromatography High Pressure Liquidmedia_commonmedicine.drugJournal of chromatography. B, Biomedical sciences and applications
researchProduct

Carbamazepine transbuccal delivery: the histo-morphological features of reconstituted human oral epithelium and buccal porcine mucosae in the transmu…

2009

Transbuccal drug delivery is an attractive way of administration since several well-known advantages are provided, especially with respect to peroral management. Carbamazepine (CBZ) is an anticonvulsant which is useful in controlling neuropathic pain, and it is currently administered by peroral route, although its absorption and bioavailability is limited due to various factors. The oral cavity could be an interesting site for transbuccal CBZ delivery due to two properties: slow administration of constant low drug doses and less dose-related side effects. However, in transbuccal absorption a major limitation could be the low permeability of the mucosa which results in low drug bioavailabil…

DrugSwinemedicine.medical_treatmentmedia_common.quotation_subjectImmunologyAbsorption (skin)PharmacologyPermeabilitymedicineImmunology and AllergyAnimalsHumansmedia_commonPharmacologyChemistryMouth MucosaCarbamazepineBuccal administrationEpitheliumCarbamazepine Transbuccal drug delivery Porcine buccal mucosa Reconstituted human oral epithelium Trigeminal neuralgiaBioavailabilityAnticonvulsantmedicine.anatomical_structureCarbamazepineCheekDrug deliveryAnticonvulsantsmedicine.drugInternational journal of immunopathology and pharmacology
researchProduct

Prophylaxis of hemicrania continua: two new cases effectively treated with topiramate.

2007

Hemicrania continua (HC) is an uncommon and under-recognized primary headache disorder characterized by a strictly unilateral continuous headache of moderate intensity with possible exacerbations and associated with ipsilateral autonomic features. HC has generally a prompt and enduring response to indomethacin although 25% to 50% of treated patients develop gastrointestinal side effects. These cases pose a difficult management challenge as no other drug is consistently effective in HC. Recently 2 HC patients responsive to topiramate treatment have been reported. Here we describe 2 more patients effectively treated with topiramate. Neither reported any side effects and one had persisting res…

DrugTopiramateAdultmedia_common.quotation_subjectmedicine.medical_treatmentIndomethacinNeurological disorderFructoseCentral nervous system diseaseDrug withdrawalPrimary headacheTopiramateProfilaxismedicineHumansmedia_commonbusiness.industryAnti-Inflammatory Agents Non-SteroidalHeadacheHemicrania continuaMiddle Agedmedicine.diseaseAnticonvulsantNeurologyHemicrania continuaAnesthesiaGastritisRetreatmentSettore MED/26 - NeurologiaAnticonvulsantsFemaleNeurology (clinical)businessmedicine.drugHeadache
researchProduct

Rash and multiorgan dysfunction following lamotrigine: could genetic be involved?

2015

We report the case of a 38-year-old woman treated with lamotrigine who experienced multi-organ dysfunction. The patient received the drug at the dose of 100 mg per day. One week later, the treatment was suspended because of an extensive body rash. Twenty-four hours later, the patient appeared drowsy and stuporous and was hospitalized. On the fifth day, the patient was admitted with a clinical picture of acute multi-organ failure in our Institute, where, she, despite the support of vital functions with vasoactive drugs, continuous hemofiltration and ventilation with oxygen, died. Serum lamotrigine concentration was measured 110 h after its last dose and the drug resulted to be still present …

DrugUGT1A4Genotypemedia_common.quotation_subjectMultiple Organ FailurePharmaceutical ScienceSNPPharmacyLamotrigineToxicologyLamotriginePolymorphism Single NucleotideVasoactiveRashmedicineHumansPharmacology (medical)GlucuronosyltransferaseUGT2B7media_commonPharmacologybusiness.industryTriazinesPharmacogeneticMultiorgan dysfunctionABCB1ExanthemaRashHLAMulti-organ dysfunctionAnesthesiaBreathingSettore BIO/14 - FarmacologiaAnticonvulsantsFemaleUGT1A4medicine.symptombusinessPharmacogeneticsAntiepileptic drugmedicine.drug
researchProduct